Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With ETV6-NTRK3 Fusion-Positive Carcinoma Harboring the NTRK3G623R Solvent-Front Mutation. (2021)

Record Type:
Journal Article
Title:
Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With ETV6-NTRK3 Fusion-Positive Carcinoma Harboring the NTRK3G623R Solvent-Front Mutation. (2021)
Main Title:
Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With ETV6-NTRK3 Fusion-Positive Carcinoma Harboring the NTRK3G623R Solvent-Front Mutation
Authors:
Hanf, Dorothea
Heining, Christoph
Laaber, Karin
Nebelung, Heiner
Uhrig, Sebastian
Hutter, Barbara
Jahn, Arne
Richter, Daniela
Aust, Daniela
Herbst, Friederike
Fröhling, Stefan
Glimm, Hanno
Folprecht, Gunnar
Abstract:
Is Part Of:
JCO precision oncology. Volume 5(2021)
Journal:
JCO precision oncology
Issue:
Volume 5(2021)
Issue Display:
Volume 5, Issue 2021 (2021)
Year:
2021
Volume:
5
Issue:
2021
Issue Sort Value:
2021-0005-2021-0000
Page Start:
Page End:
Publication Date:
2021
Subjects:
Precision Medicine
Neoplasms
Pharmacogenetics
Molecular Targeted Therapy
Personalized medicine
Oncology
Pharmacogenomics
Periodical
Periodicals
616.994
Journal URLs:
http://po.jco.org ↗
http://journals.lww.com/pages/default.aspx ↗
DOI:
10.1200/PO.20.00278 ↗
Languages:
English
ISSNs:
2473-4284
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
22882.xml